BACKGROUND: The objective of this study was to test the activity and toxicity of epirubicin plus docetaxel as primary chemotherapy for women with large, operable (T2; > 3 cm) or locally advanced (Stage III) breast carcinoma, including patients with inflammatory breast carcinoma. METHODS: In this single-center, open-label, single-stage, Phase II trial, epirubicin (75 mg/m(2); intravenous bolus) followed by docetaxel (80 mg/m(2); 1-hour intravenous infusion) was administered on Day 1 of each cycle for four cycles. RESULTS: Nine of 30 patients (30%) had inflammatory breast carcinoma. Twenty-three patients (76.7%; 95% confidence interval, 57.7-90.1) had a clinical objective response that was complete in 6 patients (20%). Twenty-seven patients (90%) underwent surgery that was conservative in 5 patients (16.7%). Pathologic response evaluation revealed four complete responses (13.3%; 95% confidence interval, 3.8-30.7). Grade 4 neutropenia was recorded in 80.0% of patients, and febrile neutropenia was recorded in one-third of patients. Anemia and thrombocytopenia were never severe. Other side effects were diarrhea (26.6%), oral mucositis (43.3%), and emesis (26.6%). CONCLUSIONS: Neoadjuvant chemotherapy with epirubicin plus docetaxel was a feasible treatment and was active in an unfavorable series of patients with locally advanced breast carcinoma, including patients with inflammatory breast carcinoma. Copyright 2002 American Cancer Society.DOI 10.1002/cncr.20335
BACKGROUND: The objective of this study was to test the activity and toxicity of epirubicin plus docetaxel as primary chemotherapy for women with large, operable (T2; > 3 cm) or locally advanced (Stage III) breast carcinoma, including patients with inflammatory breast carcinoma. METHODS: In this single-center, open-label, single-stage, Phase II trial, epirubicin (75 mg/m(2); intravenous bolus) followed by docetaxel (80 mg/m(2); 1-hour intravenous infusion) was administered on Day 1 of each cycle for four cycles. RESULTS: Nine of 30 patients (30%) had inflammatory breast carcinoma. Twenty-three patients (76.7%; 95% confidence interval, 57.7-90.1) had a clinical objective response that was complete in 6 patients (20%). Twenty-seven patients (90%) underwent surgery that was conservative in 5 patients (16.7%). Pathologic response evaluation revealed four complete responses (13.3%; 95% confidence interval, 3.8-30.7). Grade 4 neutropenia was recorded in 80.0% of patients, and febrile neutropenia was recorded in one-third of patients. Anemia and thrombocytopenia were never severe. Other side effects were diarrhea (26.6%), oral mucositis (43.3%), and emesis (26.6%). CONCLUSIONS: Neoadjuvant chemotherapy with epirubicin plus docetaxel was a feasible treatment and was active in an unfavorable series of patients with locally advanced breast carcinoma, including patients with inflammatory breast carcinoma. Copyright 2002 American Cancer Society.DOI 10.1002/cncr.20335
Authors: Zsolt Horváth; László Torday; Erika Hitre; Erna Ganofszky; Eva Juhos; Ferenc Czeglédi; László Urbán; Csaba Polgár; István Láng; Sándor Eckhardt; Miklós Kásler Journal: Pathol Oncol Res Date: 2010-12-14 Impact factor: 3.201
Authors: Bala Basak Oven Ustaalioglu; Mahmut Gumus; Ahmet Bilici; Mesut Seker; Faysal Dane; Taflan Salepci; Tarik Salman; Mehmet Aliustaoglu; Mehmet Eser; Cem Gezen; Mustafa Yaylaci; Nazim Serdar Turhal Journal: Med Oncol Date: 2009-06-02 Impact factor: 3.064
Authors: Francesco Nuzzo; Alessandro Morabito; Adriano Gravina; Francesca Di Rella; Gabriella Landi; Carmen Pacilio; Vincenzo Labonia; Emanuela Rossi; Ermelinda De Maio; Maria Carmela Piccirillo; Giuseppe D'Aiuto; Renato Thomas; Massimo Rinaldo; Gerardo Botti; Maurizio Di Bonito; Massimo Di Maio; Ciro Gallo; Francesco Perrone; Andrea de Matteis Journal: BMC Cancer Date: 2011-02-16 Impact factor: 4.430